Loading company…
San Francisco oncology company developing Palazestrant, an oral treatment for advanced ER-positive, HER2-negative breast cancer.
Olema Pharmaceuticals, Inc. was founded in 2007 and operates from San Francisco, US. CEO Sean Bohen leads the company, and Cyrus Harmon is its founder. Its lead candidate, Palazestrant (OP-1250), is a once-daily oral treatment for advanced ER-positive, HER2-negative breast cancer after prior treatment. On November 18, 2020, it raised USD 50.00 mn in venture debt led by Silicon Valley Bank, and its November 2020 IPO raised USD 209.00 mn on Nasdaq at USD 19 per share.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in